Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients

摘要: // Jiwon Koh 1 , Chan-Young Ock 2 Jin Won Kim 3 Soo Kyung Nam 4 Yoonjin Kwak Sumi Yun 5 Sang-Hoon Ahn 6 Do Joong Park Hyung-Ho Woo Ho Hye Seung Lee Department of Pathology, Seoul National University College Medicine, Jongno-gu, 03080, Republic Korea Internal Hospital, Bundang Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Soonchunhyang Yongsan-gu, 04401, Surgery, Correspondence to: Lee, email: hye2@snu.ac.kr Keywords: gastric cancer, programmed cell death ligand 1, tumor-infiltrating lymphocytes, cancer microenvironment Received: November 22, 2016      Accepted: February 06, 2017      Published: 17, 2017 ABSTRACT We co-assessed PD-L1 expression and CD8 + lymphocytes in (GC), categorized into immune types. Immunohistochemistry ( CD8, Foxp3, E-cadherin, p53), mRNA situ hybridization (ISH), microsatellite instability (MSI), EBV ISH were performed 392 stage II/III GCs treated with curative surgery fluoropyrimidine-based adjuvant chemotherapy, two public genome databases analyzed for validation. was found 98/392 (25.0%). The proportions types are as follows: /CD8 High, 22.7%; − Low 2.3%; High 52.3%. type accounted majority MSI-high (MSI-H) (92.0% 66.7%, respectively), analysis from datasets demonstrated similar pattern. showed the best overall survival (OS) worst P < 0.001). alone not associated OS, however, compared to independent favorable prognostic factor OS by multivariate = 0.042). Adaptation recent molecular classification based on EBV, MSI, p53 no significant differences. These findings support close relationship between PD-L1/CD8 status MSI-H GCs, their significance GCs.